Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Subsidiary
- Established
- 1997-04-16
- Employees
- -
- Market Cap
- -
- Website
- http://www.cttq.com
A Phase I Clinical Trial of Bevacizumab Injection
- Conditions
- Interventions
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 98
- Registration Number
- NCT05476341
- Locations
- 🇨🇳
Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, Jilin, China
Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2022-11-02
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 220
- Registration Number
- NCT05472324
- Locations
- 🇨🇳
GUANGZHOU FIRST PEOPLE's HOSPITAL, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT05451407
- Locations
- 🇨🇳
Peking University Cancer Hospital, BeiJing, Beijing, China
Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 73
- Registration Number
- NCT05426798
- Locations
- 🇨🇳
West China Hospital of Sichuan University, ChengDu, Sichuan, China
Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid Tumors
- First Posted Date
- 2022-06-13
- Last Posted Date
- 2022-06-13
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT05416359
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳First Affiliated Hospital with Nanjin Medical University (Jiangsu Province Hospital), Nanjing, Jiangsu, China
🇨🇳Sun Yat-Sen University Cancer Canter, Guangzhou, Guangdong, China
To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT05405439
- Locations
- 🇨🇳
Chongqing Cancer Hospital, Chongqing, Chongqing, China
🇨🇳The First Hospital of Peking University, Beijing, Beijing, China
🇨🇳The Southwest Hospitai of Amu, Chongqing, Chongqing, China
To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-06-02
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 92
- Registration Number
- NCT05400876
- Locations
- 🇨🇳
Sichuan Cancer Hospital, Chengdu, Sichuan, China
A Clinical Trial of Safety and Tolerance of TQH3821 Tablets in Adult Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 63
- Registration Number
- NCT05380934
- Locations
- 🇨🇳
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail
- First Posted Date
- 2022-05-16
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 287
- Registration Number
- NCT05375461
- Locations
- 🇨🇳
Beijing Cancer Hosptital, Beijing, Beijing, China
🇨🇳The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China
To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 432
- Registration Number
- NCT05365178
- Locations
- 🇨🇳
The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
🇨🇳Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Gansu Provincial Cancer Hospital, Lanzhou, Gansu, China